公开(公告)号：SK23099A3

公开(公告)日：1999-08-06

申请号：SK23099

申请日：1997-08-22

Applicant: BASF AG

Inventor： STEINER GERD ,  LUBISCH WILFRIED ,  BACH ALFRED ,  EMLING FRANZ ,  WICKE KARSTEN ,  TESCHENDORF HANS-JURGEN ,  BEHL BERTHOLD ,  KERRRIGAN FRANK ,  CHEETHAM SHARON

IPC: A61K31/435 ,  A61K31/519 ,  A61P25/24 ,  A61P43/00 ,  C07D211/00 ,  C07D239/00 ,  C07D333/00 ,  C07D495/14

Abstract: The invention concerns 3-substituted 3,4,5,6,7,8-hexahydro- pyrid3':4,5]thieno-[2,3-d]pyrimidine derivatives of formula (I), their physiologically acceptable salts and use in the therapy.

公开(公告)号：AU9748498A

公开(公告)日：1999-05-17

申请号：AU9748498

申请日：1998-10-05

Applicant: BASF AG

Inventor： LUBISCH WILFRIED ,  DULLWEBER UTA ,  STARCK DOROTHEA ,  STEINER GERD ,  BACH ALFRED ,  EMLING FRANZ ,  GARCIA-LADONA XAVIER ,  TESCHENDORF HANS-JURGEN ,  WICKE KARSTEN

IPC: A61K31/519 ,  A61P1/00 ,  A61P1/14 ,  A61P3/04 ,  A61P5/00 ,  A61P9/12 ,  A61P15/00 ,  A61P25/00 ,  A61P25/22 ,  A61P25/24 ,  A61P25/28 ,  A61P43/00 ,  C07D471/00 ,  C07D471/04

Abstract: 3-substituted tetrahydropyridopyrimidinone derivatives of the formula (I) wherein the radicals have the meanings given in the Description, to a method for producing said derivatives and, to their use for producing active ingredients for drugs.

公开(公告)号：CA2305258A1

公开(公告)日：1999-05-06

申请号：CA2305258

申请日：1998-10-05

Applicant: BASF AG

Inventor： STEINER GERD ,  STARCK DOROTHEA ,  DULLWEBER UTA ,  BACH ALFRED ,  LUBISCH WILFRIED ,  EMLING FRANZ ,  GARCIA-LADONA XAVIER ,  TESCHENDORF HANS-JURGEN ,  WICKE KARSTEN

IPC: A61K31/519 ,  A61P1/00 ,  A61P1/14 ,  A61P3/04 ,  A61P5/00 ,  A61P9/12 ,  A61P15/00 ,  A61P25/00 ,  A61P25/22 ,  A61P25/24 ,  A61P25/28 ,  A61P43/00 ,  C07D471/00 ,  C07D471/04

Abstract: The invention relates to 3-substituted tetrahydropyridopyrimidinone derivatives of formula (I) wherein the radicals have the meanings given in the Description, to a method for producing said derivatives, and to their use as selective 5HT1B-and 5HT1A antagonists.

公开(公告)号：DE19734444A1

公开(公告)日：1999-02-11

申请号：DE19734444

申请日：1997-08-08

Applicant: BASF AG

Inventor： STEINER GERD ,  DULLWEBER UTA ,  STARCK DOROTHEA ,  BACH ALFRED ,  WICKE KARSTEN ,  TESCHENDORF HANS-JUERGEN ,  GARCIA-LADONA FRANCISCO-JAVI ,  EMLING FRANZ

IPC: A61K31/435 ,  A61P25/24 ,  C07D495/14 ,  A61K31/505

Abstract: 3-substituted 3,4,5,7-tetrahydro-pyrrolo3',4':4,5 thieno2,3-Dpyrimidine derivatives of formula (I), in which the substituents have the meaning given in the description, their preparation and their use as medicaments.

公开(公告)号：BG101112A

公开(公告)日：1998-04-30

申请号：BG10111297

申请日：1997-01-06

Applicant: BASF AG

Inventor： HELLENDAHL BEATE ,  LANSKY ANNEGRET ,  RENDENBAUH-MUELLER BEATRICE ,  BACH ALFRED ,  UNGER LILIANE ,  IESCHENDORF HANS-JUERGEN ,  WICKE CARSTEN

IPC: C07D233/84 ,  A61K31/33 ,  A61K31/415 ,  A61K31/44 ,  A61K31/4402 ,  A61K31/4406 ,  A61K31/4409 ,  A61K31/4418 ,  A61K31/4425 ,  A61K31/445 ,  A61K31/495 ,  A61K31/496 ,  A61P25/18 ,  A61P25/20 ,  A61P25/24 ,  A61P25/26 ,  C07D213/56 ,  C07D213/64 ,  C07D213/65 ,  C07D213/70 ,  C07D213/73 ,  C07D213/79 ,  C07D213/81 ,  C07D233/90 ,  C07D307/79 ,  C07D333/24 ,  C07D333/28 ,  C07D333/38 ,  C07D471/18

Abstract: The invention relates to the use of heterocyclic compoundswith the formula Het-A-Ar, where Het, A, B & Ar have the meaningslisted in the description. The compounds have high affinity todiopamin-D3-receptors and for this reason are used for thetreatment of diseases reacting to dopamin-D3-ligands.12 claims

公开(公告)号：NO970164A

公开(公告)日：1997-03-14

申请号：NO970164

申请日：1997-01-14

Applicant: BASF AG

Inventor： HELLENDAHL BEATE ,  LANSKY ANNEGRET ,  RENDENBACH-MUELLER BEATRICE ,  BACH ALFRED ,  UNGER LILIANE ,  TESCHENDORF HANS-JUERGEN ,  WICKE KARSTEN

IPC: C07D277/22 ,  A61K31/425 ,  A61K31/426 ,  A61K31/433 ,  A61K31/44 ,  A61K31/4439 ,  A61K31/454 ,  A61K31/496 ,  A61K31/54 ,  C07D277/20 ,  C07D277/32 ,  C07D277/36 ,  C07D277/42 ,  C07D285/12 ,  C07D285/125 ,  C07D285/135 ,  C07D417/12 ,  A61K31/495 ,  A61K31/41 ,  A61K31/445

CPC classification number: C07D285/125 ,  A61K31/4439 ,  A61K31/454 ,  A61K31/496 ,  C07D277/36 ,  C07D285/135 ,  C07D417/12

公开(公告)号：ZA955869B

公开(公告)日：1997-01-14

申请号：ZA955869

申请日：1995-07-14

Applicant: BASF AG

Inventor： HELLENDAHL BEATE ,  LANSKY ANNEGRET ,  RENDENBACH-MUELLER BEATRICE ,  BACH ALFRED ,  UNGER LILIANE ,  TESCHENDORF HANS-JUERGEN ,  WICKE KARSTEN

IPC: C07D277/22 ,  A61K31/425 ,  A61K31/426 ,  A61K31/433 ,  A61K31/435 ,  A61K31/44 ,  A61K31/4439 ,  A61K31/445 ,  A61K31/454 ,  A61K31/496 ,  A61K31/54 ,  C07D277/20 ,  C07D277/32 ,  C07D277/36 ,  C07D277/42 ,  C07D285/12 ,  C07D285/125 ,  C07D285/135 ,  C07D417/12 ,  C07D ,  A61K

Abstract: PCT No. PCT/EP95/02783 Sec. 371 Date Jan. 14, 1997 Sec. 102(e) Date Jan. 14, 1997 PCT Filed Jul. 14, 1995 PCT Pub. No. WO96/02249 PCT Pub. Date Feb. 1, 1996The present invention relates to the use of thiazole and thiadiazole compounds of the following formula: where R1, A, B and Ar have the meanings stated in the description. The compounds according to the invention have a high affinity for the dopamine D3 receptor and can therefore be used to treat disorders of the central nervous system.

公开(公告)号：NO970164D0

公开(公告)日：1997-01-14

申请号：NO970164

申请日：1997-01-14

Applicant: BASF AG

Inventor： HELLENDAHL BEATE ,  LANSKY ANNEGRET ,  RENDENBACH-MUELLER BEATRICE ,  BACH ALFRED ,  UNGER LILIANE ,  TESCHENDORF HANS-JUERGEN ,  WICKE KARSTEN

IPC: C07D277/22 ,  A61K31/425 ,  A61K31/426 ,  A61K31/433 ,  A61K31/435 ,  A61K31/44 ,  A61K31/4439 ,  A61K31/445 ,  A61K31/454 ,  A61K31/496 ,  A61K31/54 ,  C07D277/20 ,  C07D277/32 ,  C07D277/36 ,  C07D277/42 ,  C07D285/12 ,  C07D285/125 ,  C07D285/135 ,  C07D417/12

Abstract: PCT No. PCT/EP95/02783 Sec. 371 Date Jan. 14, 1997 Sec. 102(e) Date Jan. 14, 1997 PCT Filed Jul. 14, 1995 PCT Pub. No. WO96/02249 PCT Pub. Date Feb. 1, 1996The present invention relates to the use of thiazole and thiadiazole compounds of the following formula: where R1, A, B and Ar have the meanings stated in the description. The compounds according to the invention have a high affinity for the dopamine D3 receptor and can therefore be used to treat disorders of the central nervous system.

公开(公告)号：NO970163D0

公开(公告)日：1997-01-14

申请号：NO970163

申请日：1997-01-14

Applicant: BASF AG

Inventor： HELLENDAHL BEATE ,  LANSKY ANNEGRET ,  RENDENBACH-MUELLER BEATRICE ,  BACH ALFRED ,  UNGER LILIANE ,  TESCHENDORF HANS-JUERGEN ,  WICKE KARSTEN

IPC: A61K31/33 ,  C07D233/84 ,  A61K31/415 ,  A61K31/44 ,  A61K31/4402 ,  A61K31/4406 ,  A61K31/4409 ,  A61K31/4418 ,  A61K31/4425 ,  A61K31/445 ,  A61K31/495 ,  A61K31/496 ,  A61P25/18 ,  A61P25/20 ,  A61P25/24 ,  A61P25/26 ,  C07D213/56 ,  C07D213/64 ,  C07D213/65 ,  C07D213/70 ,  C07D213/73 ,  C07D213/79 ,  C07D213/81 ,  C07D233/90 ,  C07D307/79 ,  C07D333/24 ,  C07D333/28 ,  C07D333/38 ,  C07D471/18

Abstract: PCT No. PCT/EP95/02782 Sec. 371 Date Jan. 14, 1997 Sec. 102(e) Date Jan. 14, 1997 PCT Filed Jul. 14, 1995 PCT Pub. No. WO96/02246 PCT Pub. Date Feb. 1, 1996The present invention relate to the use of heterocyclic compounds of the following formula:Het-A-B-Arwhere Het, A, B and Ar have the meanings stated in the description. The compounds according to the invention have a high affinity for the dopamine D3 receptor and can therefore be used to treat disorders which respond to dopamine D3 ligands.

公开(公告)号：FI970149A

公开(公告)日：1997-01-14

申请号：FI970149

申请日：1997-01-14

Applicant: BASF AG

Inventor： HELLENDAHL BEATE ,  LANSKY ANNEGRET ,  RENDENBACH-MUELLER BEATRICE ,  BACH ALFRED ,  UNGER LILIANE ,  TESCHENDORF HANS-JUERGEN ,  WICKE KARSTEN

IPC: C07D277/22 ,  A61K31/425 ,  A61K31/426 ,  A61K31/433 ,  A61K31/435 ,  A61K31/44 ,  A61K31/4439 ,  A61K31/445 ,  A61K31/454 ,  A61K31/496 ,  A61K31/54 ,  C07D277/20 ,  C07D277/32 ,  C07D277/36 ,  C07D277/42 ,  C07D285/12 ,  C07D285/125 ,  C07D285/135 ,  C07D417/12 ,  A61K

Abstract: PCT No. PCT/EP95/02783 Sec. 371 Date Jan. 14, 1997 Sec. 102(e) Date Jan. 14, 1997 PCT Filed Jul. 14, 1995 PCT Pub. No. WO96/02249 PCT Pub. Date Feb. 1, 1996The present invention relates to the use of thiazole and thiadiazole compounds of the following formula: where R1, A, B and Ar have the meanings stated in the description. The compounds according to the invention have a high affinity for the dopamine D3 receptor and can therefore be used to treat disorders of the central nervous system.